Compugen to Present at Key Healthcare Conferences Amid Pipeline Advancements
Event summary
- Compugen management to participate in Oppenheimer and Leerink investor conferences in late February and early March 2026.
- Fireside chats scheduled for February 26 (virtual) and March 9 (in-person in Miami).
- Company advancing multiple AI-driven immunotherapy programs, including Phase 3 bispecific antibody with AstraZeneca.
- Key pipeline assets include COM902 (anti-TIGIT), COM701 (anti-PVRIG), and GS-0321 (anti-IL-18, licensed to Gilead).
The big picture
Compugen's participation in high-profile investor conferences comes as the company advances its AI-powered immunotherapy pipeline. The strategic focus on Fc-reduced antibodies and bispecific formats aligns with industry trends toward more targeted cancer treatments. With key programs in Phase 1 and Phase 3 development, the upcoming presentations will be closely watched for updates on clinical progress and partnership potential.
What we're watching
- Pipeline Momentum
- Whether Compugen can translate its AI-driven discovery platform into clinical successes across multiple programs.
- Partnership Strategy
- How the company leverages existing collaborations with AstraZeneca and Gilead to accelerate development timelines.
- Investor Sentiment
- The market's reaction to pipeline updates and the pace of potential regulatory milestones in 2026.
Related topics